Moreover, it was noted that the combination of ATR inhibitor AZD6738 and oxaliplatin are a potential treatment strategy for reversal of the chemoresistance to oxaliplatin induced by PAK6 in patients with GC. This evidence concerns the gene PAK6 and gastric cancer.